BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 29609220)

  • 1. Burden of Psoriatic Arthritis According to Different Definitions of Disease Activity: Comparing Minimal Disease Activity and the Disease Activity Index for Psoriatic Arthritis.
    Wervers K; Vis M; Tchetveriko I; Gerards AH; Kok MR; Appels CWY; van der Graaff WL; van Groenendael JHLM; Korswagen LA; Veris-van Dieren JJ; Hazes JMW; Luime JJ
    Arthritis Care Res (Hoboken); 2018 Dec; 70(12):1764-1770. PubMed ID: 29609220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Residual symptoms and disease burden among patients with psoriatic arthritis: is a new disease activity index required?
    Kilic G; Kilic E; Nas K; Kamanlı A; Tekeoglu İ
    Rheumatol Int; 2019 Jan; 39(1):73-81. PubMed ID: 30426235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of disease activity index for psoriatic arthritis (DAPSA) and minimal disease activity (MDA) targets for patients with psoriatic arthritis: A post hoc analysis of data from phase 3 tofacitinib studies.
    Schneeberger EE; Citera G; Nash P; Smolen JS; Mease PJ; Soriano ER; Helling C; Szumski AE; Mundayat R; de León DP
    Semin Arthritis Rheum; 2023 Feb; 58():152134. PubMed ID: 36476498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of remission and low disease activity states with DAPSA, MDA and VLDA in a clinical trial setting in psoriatic arthritis patients: 2-year results from the FUTURE 2 study.
    Coates LC; Nash P; Kvien TK; Gossec L; Mease PJ; Rasouliyan L; Pricop L; Jugl SM; Gandhi KK; Gaillez C; Smolen JS
    Semin Arthritis Rheum; 2020 Aug; 50(4):709-718. PubMed ID: 32521325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparing patient-perceived and physician-perceived remission and low disease activity in psoriatic arthritis: an analysis of 410 patients from 14 countries.
    Gorlier C; Orbai AM; Puyraimond-Zemmour D; Coates LC; Kiltz U; Leung YY; Palominos P; Cañete JD; Scrivo R; Balanescu A; Dernis E; Tälli S; Ruyssen-Witrand A; Soubrier M; Aydin SZ; Eder L; Gaydukova I; Lubrano E; Kalyoncu U; Richette P; Husni ME; de Wit M; Smolen JS; Gossec L
    Ann Rheum Dis; 2019 Feb; 78(2):201-208. PubMed ID: 30442648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Composite Indices Tailored for Psoriatic Arthritis Treated with csDMARD and bDMARD: A Cross-sectional Analysis of a Longitudinal Cohort.
    Lubrano E; De Socio A; Perrotta FM
    J Rheumatol; 2017 Aug; 44(8):1159-1164. PubMed ID: 28572467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Different Remission and Low Disease Definitions in Psoriatic Arthritis and Evaluation of Their Prognostic Value.
    Coates LC; Gottlieb AB; Merola JF; Boone C; Szumski A; Chhabra A
    J Rheumatol; 2019 Feb; 46(2):160-165. PubMed ID: 30323006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Remission and low disease activity in psoriatic arthritis publications: a systematic literature review with meta-analysis.
    Hagège B; Tan E; Gayraud M; Fautrel B; Gossec L; Mitrovic S
    Rheumatology (Oxford); 2020 Aug; 59(8):1818-1825. PubMed ID: 32118267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score.
    Schoels MM; Aletaha D; Alasti F; Smolen JS
    Ann Rheum Dis; 2016 May; 75(5):811-8. PubMed ID: 26269398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of the Patient Acceptable Symptom State (PASS) in psoriatic arthritis: association with disease activity and quality of life indices.
    Lubrano E; Scriffignano S; Azuaga AB; Ramirez J; Cañete JD; Perrotta FM
    RMD Open; 2020 Mar; 6(1):. PubMed ID: 32179713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disease activity states of the DAPSA, a psoriatic arthritis specific instrument, are valid against functional status and structural progression.
    Aletaha D; Alasti F; Smolen JS
    Ann Rheum Dis; 2017 Feb; 76(2):418-421. PubMed ID: 27457512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient's Global Assessment as an Outcome Measure for Psoriatic Arthritis in Clinical Practice: A Surrogate for Measuring Low Disease Activity?
    Lubrano E; Perrotta FM; Parsons WJ; Marchesoni A
    J Rheumatol; 2015 Dec; 42(12):2332-8. PubMed ID: 26523033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early psoriatic arthritis: short symptom duration, male gender and preserved physical functioning at presentation predict favourable outcome at 5-year follow-up. Results from the Swedish Early Psoriatic Arthritis Register (SwePsA).
    Theander E; Husmark T; Alenius GM; Larsson PT; Teleman A; Geijer M; Lindqvist UR
    Ann Rheum Dis; 2014 Feb; 73(2):407-13. PubMed ID: 23355078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Residual Disease Activity and Associated Factors in Psoriatic Arthritis.
    Lubrano E; Scriffignano S; Perrotta FM
    J Rheumatol; 2020 Oct; 47(10):1490-1495. PubMed ID: 31676704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ideal target for psoriatic arthritis? Comparison of remission and low disease activity states in a real-life cohort.
    van Mens LJJ; van de Sande MGH; van Kuijk AWR; Baeten D; Coates LC
    Ann Rheum Dis; 2018 Feb; 77(2):251-257. PubMed ID: 29080861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of Response to Treatment, Remission, and Minimal Disease Activity in Axial Psoriatic Arthritis Treated with Tumor Necrosis Factor Inhibitors.
    Lubrano E; Parsons WJ; Perrotta FM
    J Rheumatol; 2016 May; 43(5):918-23. PubMed ID: 26980581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Composite Measure Remission Targets in Psoriatic Arthritis.
    Farkas F; Ikumi N; Elmamoun M; Szentpetery A; FitzGerald O
    J Rheumatol; 2021 Aug; 48(8):1272-1278. PubMed ID: 33722944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Need for Improvement in Current Treatment of Psoriatic Arthritis: Study of an Outpatient Clinic Population.
    Michelsen B; Diamantopoulos AP; Høiberg HK; Soldal DM; Kavanaugh A; Haugeberg G
    J Rheumatol; 2017 Apr; 44(4):431-436. PubMed ID: 28148701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treat to target and prevention of subclinical atherosclerosis in psoriatic arthritis-which target should we choose?
    Cheng IT; Li EK; Wong PC; Law MY; Yim IC; Lai BT; Ying SK; Kwok KY; Li M; Li TK; Lee JJ; Szeto CC; Yan BP; Lee AP; Tam LS
    Rheumatology (Oxford); 2020 Oct; 59(10):2881-2892. PubMed ID: 32087023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patients with longstanding pPatients with longstanding psoriatic arthritis can achieve DAPSA remission or low disease activity and it correlates to better functional outcomes: results from a Latin-American real-life cohort.
    Cruz LV; Farani JB; Costa JR; de Andrade Águas JV; Ruschel B; de Almeida Menegat F; Gasparin AA; Brenol CV; Kohem CL; Bessa A; Forestiero F; Thies F; Palominos PE
    Adv Rheumatol; 2024 Jan; 64(1):3. PubMed ID: 38167571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.